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Abstract 
Background: We conducted a study to assess the frequency and distribution patterns of selected opportunistic 
infections (OIs) and opportunistic cancers (OCs) in different geographical areas before and after HAART in Uganda.
Methods: This was a cross‑sectional serial review of observation data for adult HIV positive patients (≥15 years) 
enrolled with the AIDS support organization (TASO) in Uganda covering the period from January 2001 to December 
2013. Both AIDS defining OIs/OCs and non‑AIDS defining OIs were analyzed. The study period was structured into 
three time periods: “pre‑ HAART” (2001–2003), “early‑HAART” (2004–2008) and “late‑HAART” (2009–2013). Descriptive 
statistics were used to summarize the data by time period, age, gender and geographical location. Chi squared test 
used to test the significance of the differences in proportions.
Results: A total of 108,619 HIV positive patients were included in the analysis. 64% (64,240) were female with median 
age of 33 years (IQR 27–40). The most frequent OIs before HAART were oral candida (34.6%) diarrhoeal infection 
(<1 month) (30.6%), geohelminths (26.5%), Mycobacterium tuberculosis (TB) (17.7%), malaria (15.1%) and bacterial 
pneumonia (11.2%). In early HAART (2004–2008), the most frequent OIs were geohelminths (32.4%), diarrhoeal infec‑
tion (25.6%), TB (18.2%) and oral candida (18.1%). In late HAART (2009–2013), the most frequent OIs were geohel‑
minths (23.5%) and diarrhoeal infection (14.3%). By gender, prevalence was consistently higher in women (p < 0.05) 
before and after HAART for geohelminths, candidiasis, diarrhoeal infection, bacterial pneumonia and genital ulcer 
disease but consistently higher in men for TB and Kaposi’s sarcoma (p < 0.05). By age, prevalence was consistently 
higher in older age groups (>30 years) before and after HAART for oral candida and TB (p < 0.05) and higher in young 
age groups (<30 years) for malaria and genital ulcers (p < 0.05). By geographical location, prevalence was consistently 
higher in Eastern and Northern Uganda before and after HAART for diarrheal infection and geohelminths (p < 0.0001).
Conclusions: The frequency and pattern of OIs before and after HAART differs by gender, age and geographical loca‑
tion. Prevalence of geohelminths and diarrhea infection(<1 month) remains high especially in Northern and Eastern 
Uganda even after HAART and should therefore be given special attention in HIV/AIDS care programmes in these 
settings.
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Background
The human immunodeficiency virus (HIV) epidemic 
remains one of the greatest global health challenge of 
the 21st century [1] in the absence of an effective vac-
cine or curative therapy. According to the Joint United 
Nations Programme on HIV/AIDS (UNAIDS), 36.7 mil-
lion people worldwide were estimated to be living with 
this deadly virus by end of 2015 of which 25.5 million 
(69.5%) were in sub-Saharan Africa [1]. Since the out-
break of the HIV pandemic, an estimated 34 million 
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people worldwide have died and sub-Saharan Africa 
accounts for almost 70% of the total deaths [2]. How-
ever, with increased access to highly active antiretroviral 
therapy (HAART), there has been tremendous improve-
ment in survival and quality of life among persons living 
with HIV globally. Latest UNAIDS data shows by end of 
2015, close to 17 million persons living with HIV globally 
were on HAART with subsequent reduction in mortality 
of 43% [1].
Opportunistic infections (OIs) associated with HIV 
remain the single main cause of ill-health and death 
among HIV/AIDS patients in resource poor settings [3–
5]. OIs lower the quality of life of HIV infected persons, 
speeds up the rate of progression to fully blown AIDS, 
reduces patients’ response to antiretroviral treatment 
especially when HIV-positive patients are co-infected 
with tuberculosis, increases stigma and limits one’s abil-
ity to work and are usually associated with high medical 
care costs [6, 7]. OIs have therefore greatly contributed 
to poverty among those infected and affected by HIV/
AIDS and hence an impediment to the attainment of the 
sustainable development goal (SDG) three on health in 
resource poor settings.
Although the natural history of HIV tends to be similar 
in most patients, the patterns of OIs that largely define 
the symptomatic and clinical manifestation of HIV infec-
tion tend to vary in different regions of the world [4, 8, 9]. 
Thus, while HIV patients in developed countries rarely 
suffer from bacterial and protozoal infections, they are a 
major cause of morbidity and mortality in resource-poor 
settings [4, 9, 10]. Though, the introduction of highly 
active antiretroviral therapy (HAART) has substantially 
reduced the risk of suffering from an opportunistic infec-
tion [11], HIV positive patients in resource poor settings 
continue to suffer from opportunistic infections due to 
several factors including late HIV diagnosis, sub-optimal 
HAART use, poor adherence, dug resistance, poverty, 
poor nutrition, high exposure to infectious agents, just to 
mention a few [10, 12–17].
Uganda is one of the few sub-Saharan countries in 
which the magnitude of the HIV epidemic has been 
substantially reduced and stabilized in the past decades; 
though recent reports show a slight increase in HIV 
prevalence among adults from a national average of 6.4% 
in 2005 to 7.3% in 2011 [18]. According to the Uganda 
AIDS indicator survey (2011), the burden of HIV varies 
by person (gender and age) and geographical area being 
predominantly higher in women (8.3%) compared to 
men (6.1%). By age, prevalence was found higher in older 
age groups (>35  years) [18]. Geographically, the central 
region of Uganda was shown to have the highest HIV 
prevalence (10.6%), followed by mid-northern (8.3%) 
and then mid and south western (8–8.2%) and lowest 
prevalence in mid-eastern (4.1%) [18]. However, what was 
not clear was whether the burden of HIV related oppor-
tunistic infections follows the same pattern. The role of 
different OIs in morbidity before and after HAART has 
never been well documented. The purpose of this study 
was to assess the frequency, distribution patterns of dif-
ferent OIs before and after HAART in Uganda.
Methods
Study setting
The study obtained observational data from the AIDS 
support organization (TASO) known to be the oldest 
and largest HIV/AIDS care and treatment program in 
Uganda and sub-Saharan Africa. TASO was founded in 
1987 and has 11 HIV/AIDS clinics spread across Uganda 
which have been nationally recognized as centres of 
excellence (CoE) in HIV/AIDS care and treatment in 
Uganda. TASO HIV clinics offer comprehensive HIV 
treatment and care, including provision of free antiretro-
viral drugs and cotrimoxazole prophylaxis, HIV testing 
and counselling, home-based care and psycho-social sup-
port to their clients. TASO HAART programme started 
as part of the National HAART roll-out programme in 
public health facilities in Uganda. Being one of the larg-
est HAART providers in the country, TASO attracted a 
lot of support from different funders supporting HAART 
programmes in sub-Saharan Africa including the Presi-
dent’s Emergency Plan for AIDS Relief (PEPFAR) and the 
Global Fund to Fight AIDS, Tuberculosis and Malaria. 
Initially, HAART eligibility was based on WHO 2006 
guidelines i.e. WHO stage 3 or 4 illness or a CD4 cell 
count <200 cells/μl for adults and adolescents and WHO 
stage III, advanced stage II or stage I with CD4 cell per-
centage less than 20% for those more than 18 months of 
age [20]. However, in 2010 new HAART guidelines [21] 
that raised the threshold for adults and adolescents to a 
CD4 cell count ≤350 or WHO clinical stage 3 or 4 irre-
spective of CD4 cell count were adopted [22]. Those not 
eligible for HAART were offered cotrimoxazole or dap-
sone prophylaxis. Additionally TASO HAART delivery 
includes community volunteers/treatment partners that 
help to monitor HAART adherence, adverse effects, 
opportunistic infections and reporting those who die. All 
services are free of charge including anti-retroviral drugs 
(ARVs) for those who are eligible [23].
Study design
This was a serial cross-sectional review of observation 
data for adult HIV positive patients (≥15 years) obtaining 
care and treatment from the AIDS support organization 
(TASO) in Uganda covering the period from 1st January 
2001 to 31st December 2013. A total of 17 opportunis-
tic infections including 14 AIDS-defining opportunistic 
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infections (Oral candida, Esophageal candida, Mycobac-
terium tuberculosis, Genital ulcer disease, Cryptococcal 
meningitis, Herpes zoster, Bacterial pneumonia, Diar-
rhoeal infection <1  month, Cryptosporidiosis, Herpes 
simplex labialis, Cytomegalovirus, Toxoplasmosis, Pneu-
mocystis jiroveci pneumonia, Oral hairy leukoplakia), 
one opportunistic cancer (Kaposi’s sarcoma) and three 
non-AIDS defining opportunistic infections (Malaria 
and Geoheminths) were the main focus of this study. The 
study time was structured into three time periods corre-
sponding to two important milestones in HIV care and 
treatment in Uganda. The first time period was desig-
nated as “pre-HAART” (2001–2003) when HAART was 
not available. The second time period was designated as 
“early HAART” (2004–2008) when HAART access was 
limited to only severely ill patients (CD4 count ≤200 
cells/µl regardless of clinical stage or WHO stage III or 
IV disease) [19, 20]. The third time period was designated 
as “late HAART” (2009–2013) when HAART access was 
expanded to include patients with CD4 cell count >200 
cells/µl but ≤350 cells/µl or had WHO stage III or IV dis-
ease regardless of CD4 cell count [21].
Sampling and sample size
Four TASO HIV clinics were purposively selected basing 
on volume and quality of data available and geographi-
cal representation. The HIV clinics selected were TASO 
Mulago HIV clinic in central Uganda, TASO Mbarara 
HIV clinic in south-western Uganda, TASO Tororo HIV 
clinic in Eastern Uganda and TASO Gulu HIV clinic 
in Northern Uganda (Fig.  1). All HIV positive adults 
(15  years and above) who attended at least once at the 
selected HIV clinics in the period from 1st January 2001 
to 31st December 2013 were included in the study.
Data collection
TASO medical staff systematically registered the clients’ 
demographic characteristics and medical information fol-
lowing an established protocol for all TASO HIV clinics. 
In brief, clients were expected to attend the clinic at least 
once a month. At each clinic visit, data per client was col-
lected on a standardized case report form (CRF) detailing 
the client’s demographic information, clinical condition, 
medical history, OI diagnosis, ART use, prophylaxis use, 
any other treatment given and side effects/toxicities if 
any. OI diagnosis was based on WHO and Uganda minis-
try of Health guidelines [20–22, 24]. Data were then com-
piled and entered into the TASO electronic data base by 
TASO data administrator using EPIINFO vs3 in Access 
format. Monthly medical data for each participant cov-
ering the period January 2001 to December 2013 were 
extracted by the data administrator, delinked from overt 
identifiers and then handed over for analysis.
Data analysis
The extracted data were analyzed using Stata statistical 
software version 13.1 (Stata Corp, College station, Texas, 
USA). Descriptive statistics were summarized by fre-
quencies and percentages. For categorical variables, Chi 
squared test was used to test for the differences in propor-
tions and Wilcoxon rank-sum test for metric variables. 
Prevalence was calculated from the number patients ever 
diagnosed with a particular OI divided by the total num-
ber of patients who attended monthly clinic visits at least 
once in a given period. All significance tests were two 
sided with a p value <0.05 considered significant.
Results
Socio‑demographic and baseline clinical characteristics
A total of 108,619 HIV positive individuals were included 
in the analysis of which 64% were female with median age 
of 33 years (IQR 27–40). Majority were subsistence farm-
ers (83%) with primary or no education (77%), largest 
number were married (47%) and were Catholics by reli-
gion/faith (45%) (Table 1). Gulu HIV clinic in Northern 
Uganda had the largest number of Catholics (73%) While 
Mbarara HIV clinic in Western Uganda had the largest 
number of Protestants (51%). Tororo HIV clinic in East-
ern Uganda had the largest number of marrieds (54%). 
Mulago HIV clinic in Central Uganda had the largest 
number of divorcees (27%), highly educated (>secondary) 
(34%) and fewer subsistence farmers (18%).
Frequency and distribution patterns of OIs
Opportunistic infections (OIs) accounted for 99% of 
morbidity causes compared to 1% due to opportunis-
tic cancers (Kaposi’s sarcoma, Burkitti’s lymphoma and 
Malignant melanoma). Overall, from 2001 to 2013, a total 
of 291,168 OI episodes were recorded mainly caused by 
16 opportunistic infections and Kaposi’s sarcoma which 
though not an opportunistic infection but was included 
because of its infectious cause (human herpes virus 
type 8) [25]. Overall the burden of OIs was largely due 
to geohelminths (30.7%), diarrhoeal infection <1  month 
(25.5%), oral candida (19.4%), M. tuberculosis (18.3%), 
bacterial pneumonia (14.8%) and genital ulcers (10%), 
others were below 10% (Table 2).
Before HAART (2001–2003), the most frequent OIs 
were oral candida (34.6%) diarrhoea <1  month (30.6%), 
geohelminths (26.5%), M. tuberculosis (17.7%), malaria 
(15.1%) and bacterial pneumonia (11.2%), the rest were 
below 10%. In early HAART (2004–2008), the most fre-
quent OIS (>10%) were geohelminths (32.4%), diarrhoea 
<1 month (25.6%), M. tuberculosis (18.2%) and oral can-
dida (18.1%). In late HAART (2009–2013), the most 
frequent OIs (>10%) were geohelminths (23.5%) and diar-
rhoea <1 month (14.3%) (Fig. 2).
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By gender, prevalence was greater in women for most 
OIs except for M. tuberculosis and Kaposi’s sarcoma 
(Table  3). By age, prevalence was generally higher in 
older age groups (>30 years) for most OIs except malaria 
and genital ulcers which were predominantly higher in 
younger age groups [<30 years (Table 4)].
By geographical location, highest prevalence before 
HAART was observed in Tororo HIV clinic in Eastern 
Uganda for diarrhea <1  month (43.1%), geohelminths 
(40.9%) and TB (12.7%); Mbarara HIV clinic in South-
western Uganda for oral candida (43.1%) and malaria 
(16.7); Mulago HIV clinic in Central Uganda for geni-
tal ulcers (12.6%). In Early HAART, highest prevalence 
was observed: in Gulu HIV clinic in Northern Uganda 
for geohelminths (37.7%), diarrhea <1  month (36.8%), 
TB (21.0%) and malaria (10.6%); in Mbarara HIV clinic 
in South-western Uganda for oral candida (24%) and 
Mulago HIV clinic in Central Uganda for genital ulcers 
(12.6%). In late HAART, highest prevalence was observed 
in Gulu HIV clinic in Northern Uganda for geohelminths 
(26.3%) and Tororo HIV clinic in Eastern Uganda for 
diarrhea <1 month (19.0%) (Table 5).
Discussion
The study summaries clinical data representing nearly 
7% (108,619/1.6 million) of Ugandans living with HIV/
AIDS. Majority were women (64%), with low education 
(primary or none) (77%) and of very low socio-economic 
status (venders/petty traders/subsistence farmers) (76%). 
This nature of patients is comparable to other HIV posi-
tive patients found elsewhere in ART programmes in 
sub-Saharan Africa [17, 26–28]. A study in Nigeria, in 
which both pre-HAART and post-HAART data for 

















Fig. 1 Map of Uganda showing geographical location of study sites
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found to be women and more than half (50.4%) were 
of low socio-economic status [28]. Another study that 
examined data from an ART cohort in a rural hospital 
in western Uganda also found 65.3% of the beneficiar-
ies were women and 77.4% were of low socio-economic 
class (unemployed/self-employed/subsistence farmers) 
[26]. The fact that there were twice as many women than 
men in the current study is additional evidence that men 
remain under-represented in most ART programmes in 
sub-Saharan Africa with consequently less favourable 
programme outcomes.
Overall, opportunistic infections (OIs) occurred most 
and accounted for 99% of all opportunistic events com-
pared to 1% due to opportunistic cancers (Kaposi’s sar-
coma, malignant melanomas, Burkitt’s lymphoma and 
other lymphomas). This is also additional evidence that 
opportunistic infections as opposed to opportunistic 
cancers are the primary cause of morbidity and mortal-
ity among HIV positive individuals in sub-Saharan Africa 
[6]. Histoplasmosis, Mycobacterium avium complex 
were not seen in the current study providing additional 
evidence that these OIs might be absent or there is lack 
of diagnostic capacity in sub-Saharan Africa [29, 30]. The 
apparent rarity of Cytomegalovirus, Pneumocystis jiroveci 
pneumonia, Cryptosporidiosis and Toxoplasmosis in 
the current study could also be due to lack of diagnos-
tic capacity or evidence that they are rare among African 
HIV positive patients. The low prevalence of Cryptococ-
cal meningitis (CM) and Kaposi’s sarcoma (KS) could 
perhaps be due to the fact that TASO HIV clinics being 
mainly out-patient clinics and CM and KS being referral 
conditions, cases may have opted to seek for specialized 
care elsewhere. However, even other studies elsewhere 
in sub-Saharan Africa have shown low prevalence of 
both CM and KS. For example a study in Nigeria found 
prevalence of CM and KS was relatively lower at 0.6 and 
0.3% respectively compared to candidiasis (8.6%) and TB 
(7.7%) [28].
Before HAART (2001–2003) the burden of OIs, as 
expected, was indeed very high. The most common 
OIs before HAART were oral candida (34.6%), diar-
rhoeal <1  month (30.6%), geohelminths (26.5%), M. 











Gender (n = 108,619)
 Female 69,240 (64) 16,458 (62) 21,498 (67) 19,350 (63) 11,934 (62)
 Male 39,379 (36) 9966 (38) 10,803 (33) 11,433 (37) 7177 (38)
Median age (IQR) (n = 107,112) 33 (27, 40) 34 (28, 41) 33 (27, 40) 33 (27, 40) 33 (26, 40)
Occupation (n = 86,136)
 Paid employee 15,061 (17) 2337 (11) 6613 (27) 2929 (13) 3182 (18)
 Self employed 31,073 (36) 6905 (32) 10,975 (46) 5516 (24) 7677 (43)
 Subsistence farmer 34,564 (40) 11,250 (52) 4390 (18) 12,635 (56) 6289 (35)
 Others 5438 (6) 1105 (5) 2075 (9) 1485 (7) 773 (4)
Education (n = 92,840)
 None 19,712 (21) 6009 (28) 2672 (11) 6258 (21) 4773 (27)
 Primary 51,768 (56) 11,768 (54) 13,136 (55) 17,046 (58) 9818 (55)
 Secondary 17,908 (19) 3236 (15) 6831 (28) 5102 (17) 2739 (15)
 Tertiary or above 3452 (4) 640 (3) 1376 (6) 855 (3) 581 (3)
Marital status (n = 93,004)
 Single/never married 5747 (6) 1587 (7) 1652 (7) 1816 (6) 692 (4)
 Married/cohabiting 43,661 (47) 11,600 (54) 10,203 (42) 13,369 (45) 8489 (47)
 Divorced 17,138 (18) 2783 (13) 6409 (27) 4802 (16) 3144 (17)
 Widowed 21,698 (23) 4923 (23) 4739 (20) 7535 (26) 4501 (25)
 Others 4760 (5) 701 (3) 1034 (4) 1897 (6) 1128 (6)
Religion/faith (n = 91,826)
 Catholic 41,772 (45) 9169 (42) 9022 (38) 10,604 (37) 12,977 (73)
 Protestant 33,171 (36) 7166 (33) 8290 (34) 14,642 (51) 3073 (17)
 Muslim 7114 (8) 1740 (8) 3288 (14) 1627 (6) 459 (3)
 Pentecostal 6835 (7) 2440 (11) 2536 (11) 874 (3) 985 (5)
 Others 2934 (3) 1078 (5) 840 (3) 698 (2) 318 (2)
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tuberculosis (17.7%), malaria (15.1%) and bacterial pneu-
monia (11.2%). This might be because they are highly 
endemic in the country and easy to diagnose. The most 
frequent OIs after HAART (late HAART) were diar-
rhoea <1 month and geohelminths. Similar OIs were also 
observation in other previous studies in African settings 
[17, 28, 31, 32].
In the current study, oral candidiasis was the most fre-
quent opportunistic infection before HAART. According 
to Staine [6], oral candida caused by the fungus Candida 
albicans has been associated with HIV infection ever 
since HIV/AIDS was first reported in early 1980s [6]. In 
some studies in developed countries, the prevalence of 
oral candidiasis was as high as 44.8% in USA [9] and 23% 
in France [33] before HAART was introduced. A review 
of studies on HIV/AIDS related opportunistic infections 
in sub-Saharan Africa, showed the prevalence of oral 
candidiasis ranged from 14% in HIV infected pregnant 
women attending a rural hospital in Cameroon [34] to 
67% among Senegalese in patients with AIDS [35] before 
HAART. However, most studies in the HAART era, 
show that it’s prevalence has reduced but is still common 
among HIV infected persons [15, 36–38]. In Uganda, 
most studies before HAART reported high prevalence of 
oral candidiasis among HIV-infected persons [39–41]. In 
the current study we have found that the prevalence of 
oral candida has substantially reduced though not com-
pletely eliminated probably because it is endemic in the 
country and common even among those who are not 
HIV positive. The risk for oral was higher in women and 
with old age but varied by geographical area being more 
common in Mbarara in South-western Uganda. The rea-
sons for these geographical differences require further 
investigations.
In the current study, diarrhea <1  month was most 
frequent OI before and after HAART. Previous studies 
show up to 60% of people living with HIV experience 
diarrhoea, that negatively affects their quality of life and 
adherence to HAART [42]. Diarrhoea among HIV posi-
tive individuals may be due to multiple causes including 
infectious causes (bacterial, viral, protozoal, helminthic, 
etc.) or non-infectious causes(ARV drug effects e.g. 
ritonavir-boosted protease inhibitors such as lopina-
vir/ritonavir or nelfinavir) [42–46]. In Uganda, a previ-
ous study reported the commonest causes of diarrhoea 
to be helminthic infections (29.5%), bacterial infections 
(19.2%) and protozoal infections (9.2%) [47]. In the cur-
rent study we found diarrhoea <1 months was more com-
mon among women compared to men probably because 
women by nature of their traditional responsibilities tend 
to be more vulnerable than men. Prevalence of diarrhea 
<1 month was found higher among HIV positive patients 
at Gulu HIV clinic in Northern and Tororo HIV clinic 
in Eastern Uganda compare to HIV positive patients at 
Mulago HIV clinic in Central Uganda and Mbarara HIV 
clinic in South-western Uganda probably because of the 
socio-economic disparities between these regions with 
the later being relatively more developed compared to the 
former. Though preventable, the persistence of diarrhoea 
<1 month after HAART and free access to universal anti-
microbial prophylaxis needs further investigations to 
establish the actual cause.
TB caused by M. tuberculosis is one of the leading 
causes of morbidity and mortality in persons infected 
with HIV/AIDS globally [48]. Studies show that HIV 
reactivates latent TB hence increasing the risk of TB in 
HIV-infected patients [49]. In 2012, about 13% of the 
people who developed TB globally were HIV positive 
and the prevalence of TB co-infection was highest in sub-
saharan Africa [48]. In the current study, TB was among 
the most frequent OIs especially in the period before 
HAART and prevalence was higher in men compared 
to women. The sex difference is consistent with many 
other previous studies which show men were more at 
risk of suffering from TB compared to women [50, 51]. 
Table 2 Overall frequency distribution of  different types 
of  OIs among  HIV positive patients in  TASO, Uganda 
(2001–2013)
HHV8 human herpes virus type 8, n number of patients







 Geo helminthes 33,311 30.7
 Diarrhea <1 month 27,658 25.5
 Oral candida 21,053 19.4
 Mycobacterium tuberculosis 19,825 18.3
 Bacterial pneumonia 16,076 14.8
 Genital ulcer 10,887 10.0
 Confirmed malaria 8924 8.2
 Esophageal candida 8778 8.0
 Herpes zoster 7113 6.5
 Cryptosporidiosis 3551 3.3
 Cryptococcosis 1725 1.6
 Herpes simplex labialis 1367 1.3
 Cytomegalovirus 616 0.6
 Toxoplasmosis 589 0.5
 Pneumocystis carini/jiroveci pneumonia 374 0.3
 Oral hairy leukoplakia 360 0.3
 Hepatitis B or C virus 303 0.3
Opportunistic cancer
 Kaposis sarcoma/HHV8 1155 1.1
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The reason for this increased risk in men could probably 
be attributed to delayed enrolment on HAART by men 
compared to women [26]. In the current study it was also 
observed that TB was more frequent among HIV positive 
patients in Northern and Eastern Uganda compared to 
other geographical areas probably because of the socio-
economic disparities in the regions. Previous studies 
show that poverty was a strong predictor of OIs even in 
the era of HAART [28, 52]. Generally TB prevalence was 
higher in older age groups (>30 years) which is consist-
ent with other previous studies that shows TB prevalence 
increases with age [53]. A WHO TB prevalence survey 
2014 in Indonesia found that TB prevalence was almost 
five times higher in older age groups (>40  years) com-
pared to younger groups in both sexes [53].
Bacterial pneumonia (BP) caused by Streptococcus 
pneumoniae is one of the commonest respiratory tract 
infections in persons living with HIV/AIDS [4, 54–57]. 
A review of studies on HIV/AIDS related opportunistic 
infections in sub-Saharan Africa show high prevalence of 
S. pneumonia infection ranging from 25% in Cameroon 
to 31% in Uganda [4]. In our study, bacterial pneumo-
nia was one of the commonly encountered opportunis-
tic infection with an overall period prevalence of 14.8%. 
However its prevalence varied by geographical area with 
highest prevalence in Eastern Uganda. We also found BP 
Fig. 2 Bar charts showing period prevalence of selected OIs among HIV positive patients in TASO, Uganda before HAART, early and late HAART. 
sth soil transmitted helminthes, diar diarrhea, cm cryptococcal meningitis, ec esophageal candida, tb tuberculosis, oc oral candida, bp bacterial 
pneumonia, gu genital ulcer, ks Kaposis sarcoma, crysp cryptosporidiosis, hz herpes zoster, mal malaria, others (Herpes simplex labialis, Toxoplasmosis, 
Cytomegalovirus, Pneumocystis carinii/jiroveci pneumonia)
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Table 3 Chi squared test for the difference in OI prevalence by gender before and after HAART
Prevalence p value
Women (n = 16,519), n (%) Men (n = 7848), n (%)
Before HAART (2001–2003)
 Opportunistic infection
  Oral candida 5987 (36.2) 2449 (31.2) <0.0001
  Diarrhoea 5164 (31.3) 2295 (29.2) <0.0001
  Geohelminths 4544 (27.5) 1912 (24.4) <0.0001
  Mycobacterium tuberculosis 2769 (16.8) 1544 (19.7) <0.0001
  Confirmed malaria 2582 (15.6) 1087 (13.9) <0.0001
  Bacterial pneumonia 1928 (11.7) 809 (10.3) <0.0001
  Esoph candida 1620 (9.8) 567 (7.2) <0.0001
  Genital ulcer 1430 (8.7) 433 (5.5) <0.0001
  Herpes zoster 1011 (6.1) 418 (5.3) 0.025
  Cryptosporidiosis 624 (3.8) 271 (3.5) 0.076
  Cryptococcosis 275 (1.7) 152 (1.9) 0.702
  Others 301 (1.8) 90 (1.1) 0.019
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 114 (0.7) 95 (1.2) 0.068
Prevalence p value
Women (n = 38,599), n (%) Men (n = 20,232), n (%)
Early HAART (2004–2008)
 Opportunistic infection
  Geohelminths 13,205 (34.2) 5858 (29.0) <0.0001
  Diarrhoea 10,231 (26.5) 4812 (23.8) <0.0001
  Oral candida 7710 (20.0) 2961 (14.6) <0.0001
  Mycobacterium tuberculosis 3419 (16.9) 7262 (18.8) <0.0001
  Bacterial pneumonia 1741 (8.6) 2839 (7.4) <0.0001
  Genital ulcer 4461 (11.6) 1660 (8.2) <0.0001
  Esoph candida 3872 (10.0) 1456 (7.2) <0.0001
  Confirmed malaria 2482 (6.4) 1111 (5.5) 0.023
  Herpes zoster 2606 (6.8) 1152 (5.7) 0.037
  Cryptosporidiosis 1373 (3.6) 662 (3.3) 0.061
  Cryptococcosis 602 (1.6) 332 (1.6) 0.097
  Others 1260 (3.3) 539 (2.7) 0.06
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 347 (0.9) 330 (1.6) 0.012
Prevalence p value
Women (n = 40,335), n (%) Men (n = 22,547), n (%)
Late HAART (2009–2011)
 Opportunistic infection
  Geohelminths 9951 (24.7) 4852 (21.5) <0.0001
  Diarrhoea 6056 (15.0) 2917 (12.9) <0.0001
  Oral candida 3063 (7.6) 1446 (6.4) 0.029
  Bacterial pneumonia 2895 (7.2) 1453 (6.4) 0.045
  Genital ulcer 2581 (6.4) 1202 (5.3) 0.017
  Mycobacterium tuberculosis 2101 (5.2) 1489 (6.6) 0.024
  Confirmed malaria 1595 (4.0) 789 (3.5) 0.540
  Herpes zoster 1522 (3.8) 748 (3.3) 0.490
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was less in the period after HAART (2009–2013) at 8% 
compared to the period before HAART (13%) probably 
due to increased access to HAART and universal cotri-
moxazole prophylaxis. Though a conjugate pneumo-
coccal vaccine [54, 56] is now available in Uganda but 
it is still under limited access and we recommend that 
it should be availed to all HIV positive patients so as to 
reduce on the burden of bacterial pneumonia. It may be 
possible that bacterial pneumonia could have been under 
reported as in some cases, data were recorded as respira-
tory tract infection without specifying the infection.
In this study both AIDS defining and non-AIDS defin-
ing OIs were considered. Non-AIDS defining OIs found 
common among HIV positive patients in these settings 
were malaria and geohelminths. Given the geographical 
overlap of malaria and geohelminths with HIV in sub-
Saharan Africa, there is great concern of the increasing 
number of helminthic and malaria co-infections among 
HIV positive patients [58–61]. Although malaria is not 
among the WHO defined opportunistic infections diag-
nostic of AIDS [62], several studies show that malaria 
tends to occur with increased frequency and severity 
in advanced HIV-infected adults [4, 63–68]. This hap-
pens probably because HIV infection reduces resistance 
to malaria by compromising the immune system. In our 
study we found malaria was very common among HIV 
positive patients especially before HAART consistent 
with previous studies elsewhere [4, 66–68]. According to 
the World Malaria Report 2014, Uganda was ranked 3rd 
after Democratic republic of Congo and Nigeria in con-
tribution to the global burden of malaria [69]. Previous 
studies on malaria and HIV show that HIV increases vul-
nerability to malaria infection and malaria could enhance 
the progression of HIV infection to clinical AIDS in the 
absence of effective treatment [59, 70].
In the current study, prevalence of malaria men were 
less likely to suffer from malaria compared to women 
and the risk was less in those >35 years of age and var-
ied by geographical area with the western Uganda having 
the highest risk compared to other geographical areas. 
Higher prevalence of malaria in younger age groups is 
consistent with previous findings that showed malaria 
prevalence to be inversely related with age [71–73]. Geo-
graphical variation in prevalence could be influenced by 
malaria endemicity in the different geographical areas.
Though malaria prevalence among HIV positive 
patients reduced in the era of HAART, it has not been 
completely eliminated. In view of the fact that malaria 
is highly endemic in Uganda and HIV positive patients 
are highly vulnerable, malaria prevention/control should 
therefore remain an integral part of comprehensive HIV/
AIDS care in Uganda.
In the current study, geohelminths were the most com-
monly observed opportunistic infections among HIV 
positive patients before and after HAART. This is con-
sistent with other studies elsewhere in resource poor 
settings. A study in Tanzania that investigated HIV and 
parasitic co-infections among HIV positive patients 
seeking care and treatment at health facilities in Tanza-
nia found 22.1% had helminthic infections (hookworms, 
Strongyloides stercoralis, Ascaris lumbricoides, schis-
tosomes), 12.9% had malaria and 13% had both [74]. A 
related study in Rwanda that investigated the prevalence 
of soil transmitted helminthes and malaria among HIV 
positive pregnant women attending antenatal health 
centers in Rwanda found 38% had helminthic infections 
(A. lumbricoides, Trichuris trichiura, Ancylostoma duo-
denale and Necator americanus), 21% had malaria and 
10% had both [61]. Though geohelminths are not AIDS-
defining opportunistic infections, previous studies show 
that co-infection with geohelminths was associated with 
dysregulation of the immune response causing inability 
of the HIV positive patient to mount an effective immune 
response [75]. High prevalence of geohelminths can 
lead to increased prevalence of anaemia thereby wors-
ening the health conditions of persons living with HIV/
AIDS [76]. Geohelminths have also been associated 
with diarrhea, nutritional impairment, abdominal pain 
and in children they can lead to impaired cognitive and 
physical development [58]. They have also been shown to 
HHV8 human herpes virus 8, n number of patients
Table 3 continued
Prevalence p value
Women (n = 40,335), n (%) Men (n = 22,547), n (%)
  Esoph candida 1163 (2.9) 594 (2.6) 0.046
  Cryptosporidiosis 464 (1.2) 231 (1.0) 0.792
  Cryptococcosis 251 (0.6) 166 (0.7) 0.09
  Others 759 (1.9) 390 (1.7) 0.102
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 150 (0.4) 160 (0.7) 0.015
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Table 4 Chi squared test for the difference in OI prevalence by age at enrolment before and after HAART
Prevalence p value
Age < 30 (n = 8070), n (%) Age = 30–39 (n = 10,008), n (%) Age ≥ 40 (n = 6223), n (%)
Before HAART (2001–2003)
 Opportunistic infection
  Geohelminths 2187 (27.1) 2536 (25.3) 1714 (27.5) 0.058
  Diarrhoea 2422 (30.0) 3117 (31.1) 1907 (30.6) 0.671
  Oral candida 2586 (32.0) 3625 (36.2) 2213 (35.6) <0.001
  Mycobacterium tuberculosis 1350 (16.7) 1706 (17.0) 1251 (20.1) 0.031
  Bacterial pneumonia 905 (11.2) 1113 (11.1) 706 (11.3) 0.139
  Genital ulcer 667 (8.3) 802 (8.0) 390 (6.3) 0.026
  Confirmed malaria 1277 (15.8) 1518 (15.2) 863 (13.9) 0.029
  Esoph candida 654 (8.1) 945 (9.4) 585 (9.4) 0.126
  Herpes zoster 505 (6.3) 568 (5.7) 351 (5.6) 0.198
  Cryptosporidiosis 269 (1.6) 387 (1.7) 238 (1.6) 0.218
  Cryptococcosis 133 (1.6) 182 (1.8 110 (1.8) 0.707
  Others 130 (3.3) 175 (3.9) 99 (3.8) 0.168
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 57 (0.7) 104 (1.0) 48 (0.8) 0.052
Prevalence p value
Age < 30 (n = 17,872), n (%) Age = 30‑39 (n = 23,395), n (%) Age ≥ 40 (n = 16,935), n (%)
Early HAART (2004–2008)
 Opportunistic infection
  Geohelminths 5849 (32.7) 7690 (32.9) 5645 (33.3) 0.365
  Diarrhoea 4323 (24.2) 6034 (25.8) 4555 (26.9) 0.010
  Oral candida 2919 (16.3) 4510 (19.3) 3191 (18.8) <0.0001
  Mycobacterium tuberculosis 3073 (17.2) 4366 (18.7) 3150 (18.6) 0.006
  Bacterial pneumonia 1277 (7.1) 1930 (8.2) 1331 (7.9) 0.009
  Genital ulcer 1850 (10.4) 2634 (11.3) 1609 (9.5) <0.0001
  Confirmed malaria 1230 (6.9) 1366 (5.8) 883 (5.2) <0.0001
  Esoph candida 1342 (7.5) 2309 (9.9) 1648 (9.7) <0.0001
  Herpes zoster 1080 (6.0) 1554 (6.6) 1106 (6.5) 0.407
  Cryptosporidiosis 554 (2.6) 823 (3.0) 649 (3.6) 0.039
  Cryptococcosis 236 (1.3) 399 (1.7) 286 (1.7) 0.011
  Others 464 (3.1) 712 (3.5) 608 (3.8) 0.07
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 166 (0.9) 290 (1.2) 221 (1.3) 0.009
Prevalence p value
Age < 30 (n = 21,479), n (%) Age = 30‑39 (n = 23,168), n (%) Age ≥ 40 (n = 17,174), n (%)
Late HAART (2009–2013)
 Opportunistic infection
  Geohelminths 5230 (24.3) 5489 (23.7) 4119 (24.0) 0.598
  Diarrhoea 3153 (14.7) 3352 (14.5) 2372 (13.8) 0.025
  Oral candida 1442 (6.7) 1748 (7.5) 1305 (7.6) 0.015
  Mycobacterium tuberculosis 1194 (5.6) 1423 (6.1) 911 (5.3) 0.008
  Bacterial pneumonia 1481 (6.9) 1601 (6.9) 1218 (7.1) 0.673
  Genital ulcer 1454 (6.8) 1479 (6.4) 827 (4.8) <0.0001
  Confirmed malaria 934 (4.3) 896 (3.9) 524 (3.1) <0.0001
  Esoph candida 595 (2.8) 662 (2.9) 492 (2.9) 0.958
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accelerate the progression of HIV infection to AIDS [74, 
77–80] and were found associated with increased risk for 
mother-to child-transmission of HIV [60].
Globally, it is estimated that about two billion people 
are infected with geohelminths mainly in resource lim-
ited settings [75]. These infections are however, often 
neglected in national programmes and yet they exact the 
greatest burden on limited resources in these settings 
[75]. They are commonly associated with settings char-
acterised by poor sanitation and poor personal hygiene. 
Thus in most sub-Saharan Africa, the burden of helmin-
thic infections is still enormous because of the poor sani-
tation and unhygienic conditions in these settings [81, 
82].
However there were contradicting reports on the 
magnitude of helminthic infections among HIV/AIDS 
patients in resource poor settings. Some studies have 
shown higher prevalence of helminthic infections in HIV 
positive individuals compared to HIV negative controls 
[83, 84]. In contrast, others showed no significant dif-
ference in prevalence of helminthic infections between 
HIV positive patients and HIV negative controls [85, 
86]. While others showed low prevalence of helminthic 
infections among HIV positive patients compared to HIV 
negative controls [87–89]. A number of studies have also 
shown that the patterns of individual helminthic para-
sites may differ among HIV positive and HIV negative 
patients. A study in Honduras found a strong association 
between S. stercoralis and HIV infection but lower risk 
for A. lumbricoides and Trichuris trichurias [90]. Another 
study found a high prevalence of Strongyloidiasis among 
HIV-positive patients compared to HIV negative con-
trols in Brazil [91]. A related study in Ethiopia also found 
higher prevalence of S. stercoralis among HIV-positive 
patients with CD4 count <200 cells/µl [83].
In the current study, we were unable to assess this vari-
ation in intensity of infection by helminthic infection but 
we established that the prevalence of helminthic infec-
tions generally remained relatively higher compared 
to other opportunistic infections among HIV positive 
patients in Uganda even after HAART. However, more 
studies are required to have more insight on the role of 
HAART and age on severity of infection due to the differ-
ent helminthic infections.
In the current study, it was also established that preva-
lence of geohelminths was lower among men compared 
to women and higher in older age groups (>35  years). 
We also observed variation in geographical distribution 
of geohelminths with Northern and Eastern Uganda hav-
ing relatively higher burden of geohelminths than Central 
and Western Uganda. This variation in geographical dis-
tribution of geohelminths could be influenced by envi-
ronmental and socio-economic factors including poverty, 
poor sanitation and personal hygiene, ignorance, lack of 
clean water and poor quality health care. In absence of 
vaccination, the recommended public health interven-
tions would be regular deworming backed by access to 
clean water, improved sanitation and health education. 
A Cochrane systematic review of published literature on 
testing and treating HIV positive patients for intestinal 
helminthic infections showed that regular deworming 
with a single dose of albendazole is feasible in resource 
poor settings and would potentially improve survival and 
the quality of life of persons living with HIV/AIDs [75]. It 
is therefore important that regular deworming becomes 
an integral part of comprehensive HIV/AIDS care in 
Uganda and other countries in similar settings.
One of the limitations of this study was the fact that 
we used secondary data which had been collected not 
primarily for research purposes. Therefore, some vari-
ables which would have been useful in interpretation 
of our results, like patients’ viral loads, monitoring 
CD4 counts, BMI or ART adherence were missing for 
majority of the patients. These data should be targeted 
in prospective cohort studies in the future. Secondly, 
data from the four purposively selected HIV clinics 
used for this study may have not have been representa-
tive of all HIV positive individuals in Uganda which 
means generalisability could be limited to TASO pro-
gramme in Uganda. Another limitation was that CD4 
HHV8 human herpes virus 8, n number of patients
Table 4 continued
Prevalence p value
Age < 30 (n = 21,479), n (%) Age = 30‑39 (n = 23,168), n (%) Age ≥ 40 (n = 17,174), n (%)
  Herpes zoster 775 (3.6) 856 (3.7) 670 (3.9) 0.069
  Cryptosporidiosis 228 (1.7) 259 (1.7) 204 (2.2) 0.027
  Cryptococcosis 113 (0.5) 178 (0.8) 124 (0.7) 0.010
  Others 362 (1.1 405 (1.1) 374 (1.2) 0.973
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 86 (0.4) 132 (0.6) 91 (0.5) 0.055
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Table 5 Chi squared test for the difference in OI prevalence by geographical location
Prevalence p value
Tororo (Eastern Uganda) 
(n = 6534), n (%)
Mulago (Central Uganda) 
(n = 7243), n (%)
Mbarara (South‑western 
Uganda) (n = 10,586), n (%)
Before HAART (2001–2003)
 Opportunistic infection
  Geohelminths 2671 (40.9) 1406 (19.4) 2378 (22.5) <0.0001
  Diarrhoea 2817 (43.1) 1780 (24.6) 2862 (27.0) <0.0001
  Oral candida 1531 (23.4) 2345 (32.4) 4560 (43.1) <0.0001
  Bacterial pneumonia 858 (13.1) 896 (12.4) 983 (9.3) <0.0001
  Mycobacterium tuber-
culosis
830 (12.7) 875 (12.1) 608 (5.7) <0.0001
  Genital ulcer 508 (7.8) 697 (9.6) 658 (6.2) <0.0001
  Confirmed malaria 1072 (16.4) 826 (11.4) 1771 (16.7) <0.0001
  Esoph candida 261 (4.0) 732 (10.1) 1194 (11.3) <0.0001
  Herpes zoster 388 (5.9) 423 (5.8) 618 (5.8) 0.098
  Cryptosporidiosis 178 (2.7) 283 (3.9) 434 (4.1) <0.0001
  Cryptococcosis 160 (2.4) 145 (2.0) 122 (1.2) <0.0001
  Others 75 (1.1) 204 (2.8) 112 (1.1) <0.0001
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 96 (1.5) 61 (0.8) 52 (0.5) <0.0001
Prevalence p value






Mbarara (South western 
Uganda) (n = 17,047), 
n (%)




  Geohelminths 5825 (35.9) 4363 (26.8) 4925 (28.9) 3950 (37.7) <0.0001
  Diarrhoea 4503 (27.8) 3261 (20.0) 3431 (20.1) 3848 (36.8) <0.0001
  Oral candida 1966 (12.1) 3632 (22.3) 4097 (24.0) 976 (9.3) <0.0001
  Mycobacterium tuber-
culosis
2958 (18.2) 3589 (22.1) 1936 (11.4) 2198 (21.0) <0.0001
  Bacterial pneumonia 1301 (8.0) 1627 (10.0) 823 (4.8) 829 (7.9) <0.0001
  Genital ulcer 1373 (8.5) 2046 (12.6) 1474 (8.6) 1229 (11.7) <0.0001
  Confirmed malaria 893 (5.5) 984 (6.0) 611 (3.6) 1105 (10.6) <0.0001
  Esoph candida 969 (6.0) 1744 (10.7) 1714 (10.1) 901 (8.6) <0.0001
  Herpes zoster 1103 (6.8) 1110 (6.8) 970 (5.7) 575 (5.5) <0.0001
  Cryptosporidiosis 666 (4.1) 467 (2.9) 419 (2.5) 483 (4.6) <0.0001
  Cryptococcosis 238 (1.5) 337 (2.1) 197 (1.2) 162 (1.5) <0.0001
  Others 364 (2.2) 647 (4.0) 333 (2.0) 455 (4.3) <0.0001
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 209 (1.3) 195 (1.2) 128 (0.8) 145 (1.4) 0.003
Prevalence p value





Mbarara (South western 
Uganda) (15,095), n (%)




  Geohelminths 3270 (22.3) 3373 (18.8) 3169 (21.0) 3991 (26.3) <0.0001
  Diarrhoea 2786 (19.0) 1949 (10.8) 1653 (11.0) 2585 (17.1) <0.0001
  Oral candida 731 (5.0) 1822 (10.1) 1617 (10.7) 339 (2.2) <0.0001
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cell evaluations were not available for most patients 
and yet the study would have been be more informative 
if the rates of OI were reviewed in the context of CD4 
cell counts. Thirdly, some OIs were not captured in the 
data base probably because of inadequate diagnostic 
capacity. Additionally, improvements in OI diagnosis 
like introduction of the lateral flow cryptococcal Anti-
gen (CrAg) rapid tests for Cryptococcal meningitis and 
Gene Xpert for TB over time may have had an impact 
on prevalence of these OIs. Fourthly, cryptococcal 
meningitis and Kaposi’s prevalences could have been 
underestimated due to the fact they are referral condi-
tions and the study clinics only handled out patients, 
so need to be interpreted with caution. Lastly the data 
presented doesn’t prove that HAART is responsible for 
the shift in OIs. However, we believe HAART greatly 
contributed to the reduction in the frequency of OIs, 
though it may not necessarily be the only factor. Other 
factors like general improvements in the quality of care 
and availability of more potent treatment drugs (flu-
conazole, etc.), antimicrobial prophylaxis and general 
improvement in socio-economic status over time could 
have also contributed to the overall reduction in the 
prevalence of OIs.
Conclusions
Results from the current study show that the frequency 
and patterns of OIs have changed since the introduction 
of HAART in Uganda. However, these changes varied by 
type of OI, time period, age, gender and geographical loca-
tion of the HIV positive patient. Geohelminths and diar-
rheal infection <1  month remains a challenge even after 
HAART and should therefore be given special attention in 
HIV/AIDS care programmes in these settings. Our find-
ings further shows that opportunistic infections rather 
than opportunistic cancers were the primary cause of mor-
bidity accounting for 99% of all the opportunistic episodes 
among HIV positive patients in these settings. However 
compared to other geographical areas in Uganda, HIV 
positive patients in Northern and Eastern Uganda bore the 
highest burden of OIs both before and after HAART and 
therefore should be given special consideration in terms 
of resource allocation and targeted interventions so as to 
reduce the disease burden due to OIs in these areas.
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Table 5 continued
Prevalence p value





Mbarara (South western 
Uganda) (15,095), n (%)
Gulu (Northern Uganda) 
(n = 15,152), n (%)
  Bacterial pneumonia 1354 (9.2) 1043 (5.8) 641 (4.2) 1310 (8.6) <0.0001
  Mycobacterium tuber-
culosis
780 (5.3) 1088 (6.1) 436 (2.9) 1286 (8.5) <0.0001
  Genital ulcer 767 (5.2) 1047 (5.8) 1265 (8.4) 704 (4.6) <0.0001
  Confirmed malaria 769 (5.2) 688 (3.8) 365 (2.4) 562 (3.7) <0.0001
  Esoph candida 342 (2.3) 640 (3.6) 489 (3.2) 286 (1.9) <0.0001
  Herpes zoster 581 (4.0) 739 (4.1) 554 (3.7) 396 (2.6) <0.0001
  Cryptosporidiosis 219 (1.5) 198 (1.1) 140 (0.9) 138 (0.9) 0.011
  Cryptococcosis 198 (1.4) 96 (0.5) 56 (0.4) 67 (0.4) <0.0001
  Others 356 (2.4) 351 (2.0) 239 (1.6) 203 (1.3) <0.0001
 Opportunistic cancer
  Kaposi’s sarcoma/HHV8 116 (0.8) 91 (0.5) 58 (0.4) 45 (0.3) <0.0001
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